Yeda Research and Develpment & Co. Ltd

Immunobrain Checkpoint, Inc.

Kuti Baruch

Michal Eisenbach-Schwartz

Neta Rosenzweig

Jan Egebjerg

Ester Yoles

Berit Olsen Krogh

Allan Jensen

Carol David

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease

The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder

Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease

Growing community of inventors

Rehovot, Israel

Kuti Baruch